Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/Abl and P-glycoprotein expression

IUBMB Life

Volumn 65, Issue 5, 2013, Pages 435-444

  Yang, Chunhui ^a   Yang, Jingbo ^b   Sun, Meiyan ^b   Yan, Jiangzhou ^a   Meng, Xiuxiang ^a   Ma, Tonghui ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

alantolactone; apoptosis; Bcr Abl; K562 ADR; multidrug resistance; proliferation

Indexed keywords

ALANTOLACTONE; BCR ABL PROTEIN; CASPASE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOCHROME C; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN K 562; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ERYTHROLEUKEMIA CELL; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION;

APOPTOSIS; CELL PROLIFERATION; DOWN-REGULATION; DOXORUBICIN; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LACTONES; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES, EUDESMANE;

ASTERACEAE; INULA HELENIUM;

EID: 84876936613     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1141     Document Type: Article

References (40)

1. Rowley, J. D., (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290-293.
2. Lugo, T. G., Pendergast, A. M., Muller, A. J., and, Witte, O. N., (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082.
3. Daley, G. Q., Van Etten, R. A., and, Baltimore, D., (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830.
4. Kelliher, M. A., McLaughlin, J., Witte, O. N., and, Rosenberg, N., (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87, 6649-6653.
5. Kurzrock, R., Gutterman, J. U., and, Talpaz, M., (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319, 990-998.
6. Ren, R., (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172-183. (Pubitemid 40314949)
7. Bedi, A., Barber, J. P., Bedi, G. C., el-Deiry, W. S., Sidransky, D., et al. (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anti-cancer agents. Blood 86, 1148-1158.
8. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566.
9. IIImer, T., Schaich, M., Platzbecker, U., Freiberg-Richter, J., Oelschlägel, U., et al. (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18, 401-408. (Pubitemid 38425851)
10. Lyss, G., Knorre, A., Schmidt, T. J., Pahl, H. L., and, Merfort, I., (1998) The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J. Biol. Chem. 273, 33508-33516. (Pubitemid 29005734)
11. Zhang, S., Won, Y. K., Ong, C. N., and, Shen, H. M., (2005) Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr. Med. Chem. Anticancer Agents 5, 239-249. (Pubitemid 40645593)
12. Ghantous, A., Gali-Muhtasib, H., Vuorela, H., Saliba, N. A., and, Darwiche, N., (2010) What made sesquiterpene lactones reach cancer clinical trials? Drug Discov. Today 15, 668-678.
13. Lei, J. C., Yu, J. Q., Yin, Y., Liu, Y. W., and, Zou, G. L., (2012) Alantolactone induces activation of apoptosis in human hepatoma cells. Food Chem. Toxicol. 50, 3313-3319.
14. Khan, M., Yi, F., Rasul, A., Li, T., Wang, N., et al. (2012) Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction. IUBMB Life 64, 783-794.
15. Lawrence, N. J., McGown, A. T., Nduka, J., Hadfield, J. A., and, Pritchard, R. G., (2001) Cytotoxic Michael-type amine adducts of alpha-methylene lactones alantolactone and isoalantolactone. Bioorg. Med. Chem. Lett. 11, 429-431. (Pubitemid 32115864)
16. Pal, H. C., Sehar, I., Bhushan, S., Gupta, B. D., and, Saxena, A. K., (2010) Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa. Toxicol. In Vitro 24, 1599-1609.
17. Dirsch, V. M., Stuppner, H., and, Vollmar, A. M., (2001) Cytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis. Planta Med. 67, 557-559. (Pubitemid 32800426)
18. Xiang, Q. F., Wang, F., Su, X. D., Liang, Y. J., Zheng, L. S., et al. (2011) Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cell. Oncol(Dordr). 34, 33-44.
19. Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., et al. (2002) Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 62, 188-199. (Pubitemid 34074004)
20. Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J., and, Jones, R. J., (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038-2044. (Pubitemid 24112713)
21. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., et al. (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 1179-1187. (Pubitemid 24062839)
22. Litman, T., Zeuthen, T., Skovsgaard, T., and, Stein, W. D., (1997) Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta 1361, 169-176. (Pubitemid 27362090)
23. Gamet-Payrastre, L., Li, P., Lumeau, S., Cassar, G., Dupont, M. A., et al. (2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60, 1426-1433. (Pubitemid 30152017)
24. Murray, A. W., (2004) Recycling the cell cycle: cyclins revisited. Cell 116, 221-234. (Pubitemid 38167314)
25. Lu, Y. J., Yang, S. H., Chien, C. M., Lin, Y. H., Hu, X. W., et al. (2007) Induction of G2/M phase arrest and apoptosis by a novel enediyne derivative, THDB, in chronic myeloid leukemia (HL-60) cells. Toxicol. In Vitro. 21, 90-98.
26. Fujimoto, K., Hosotani, R., Doi, R., Wada, M., Lee, J. U., et al. (1999) Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int. J. Cancer 81, 637-644. (Pubitemid 29203064)
27. King, K. L., and, Cidlowski, J. A., (1998) Cell cycle regulation and apoptosis. Annu. Rev. Physiol. 60, 601-617. (Pubitemid 28157888)
28. Nurse, P., (1990) Universal control mechanism regulating onset of M-phase. Nature 344, 503-508.
29. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704. (Pubitemid 24036020)
30. Choi, Y. H., Lee, W. H., Park, K. Y., and, Zhang, L., (2000) p53-Independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn. J. Cancer Res. 91, 164-173. (Pubitemid 30130746)
31. Reed, J. C., (1998) Bcl-2 family proteins. Oncogene 17, 3225-3236. (Pubitemid 29043975)
32. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and, Newmeyer, D. D., (1997) The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, 1132-1136. (Pubitemid 27097313)
33. Shimizu, S., Narita, M., and, Tsujimoto, Y., (1999) Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399, 483-487. (Pubitemid 29258855)
34. Wen, J., You, K. R., Lee, S. Y., Song, C. H., and, Kim, D. G., (2002) Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J. Biol. Chem. 277, 38954-38964. (Pubitemid 35154761)
35. Raitano, A. B., Whang, Y. E., and, Sawyers, C. L., (1997) Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta 1333, 201-216.
36. Sánchez-García, I., and, Martín-Zanca, D., (1997) Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J. Mol. Biol. 267, 225-228. (Pubitemid 27149835)
37. Brauer, K. M., Werth, D., von Schwarzenberg, K., Bringmann, A., Kanz, L., et al. (2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res. 67, 5489-5497. (Pubitemid 46997290)
38. Gottesman, M. M., Fojo, T., and, Bates, S. E., (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58. (Pubitemid 37328807)
39. Friedrich, K., Wieder, T., Von Haefen, C., Radetzki, S., Jänicke, R., et al. (2001) Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20, 2749-2760. (Pubitemid 32549832)
40. Johnstone, R. W., Cretney, E., and, Smyth, M. J., (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93, 1075-1085. (Pubitemid 29067874)